Condition
Progressive Multiple Sclerosis (PMS)
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03523858Phase 3Active Not RecruitingPrimary
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT07006805Phase 1Withdrawn
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
NCT07583030Early Phase 1Not Yet Recruiting
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07548242Not ApplicableCompletedPrimary
The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple Sclerosis
Showing all 4 trials